descriptionPublicationkeyboard_double_arrow_right Article 01 Dec 2012 English Publisher:Springer Science and Business Media LLCJournal:Nature Biotechnology, volume 30, pages 1,186-1,190 (issn: 1087-0156, eissn: 1546-1696,

Authors: Hans C. Ebbers; Stacy A. Crow; Arnold G. Vulto; Huub Schellekens;

doi: 10.1038/nbt.2438

pmid: 23222784

Interchangeability, immunogenicity and biosimilars

- Summary
- Subjects
- Metrics

Abstract

For authorized biosimilars to achieve full acceptance in the marketplace, it is crucial that they are considered to be therapeutically equivalent and interchangeable with the brand reference product.

Related Organizations

Erasmus University Rotterdam
Netherlands
Erasmus University Medical Center
Netherlands
Utrecht University
Netherlands

Keywords

Risk Management, Therapeutic Equivalency, Humans, EMC OR-01-34-01, European Union, Biosimilar Pharmaceuticals, Drug Approval, Biotechnology

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	90
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%